

Device Maker's Quick Action on ICD Flaw Lauded

BY ALICIA AULT

Associate Editor, Practice Trends

Boston Scientific's rapid response to yet another potential safety issue with its pacemakers and implantable cardioverter defibrillators early this summer has brought praise from cardiologists who helped draft a proposal to guide responses to safety problems.

On June 23, Boston Scientific sent a letter to physicians informing them of a possibility of malfunction in a subset of two pacemaker models (Insignia and Nexus), as well as in the Contak Renewal TR and TR2 cardiac resynchronization pacemakers, and the

The word 'recall' suggests that an action should be taken, and that places physicians in an awkward and sometimes clinically inappropriate situation.'

inventory all nonimplanted devices within this well-defined subset."

Dr. Mark D. Carlson, chair of the Heart Rhythm Society Task Force on Device Performance Policies and Guidelines, lauded the company for not using the term "recall." That was one of the recommendations in the task force's April draft guidelines.

The word "has so many implications that don't necessarily apply to implantable devices," Dr. Carlson said in an interview. Recall "suggests that an action should be taken, and that places physicians in an awkward and sometimes clinically inappropriate situation," added Dr. Carlson, who is a professor of medicine and associate vice president for government relations at Case Western Reserve University in Cleveland.

In most cases, explanting a device is riskier than leaving it in, he said.

Boston Scientific said that 49,800 of the devices had been distributed, and that 27,200 had been implanted worldwide. Of those ICDs, there were five confirmed reports of malfunction associated with failure of a low-voltage capacitor from a single supplier.

Heart Attack Info For Older Adults

The National Institute on Aging has added information about heart attack to its SeniorHealth Web site, which provides health information for older Americans.

The fact sheet includes information about signs, causes, risk factors, diagnosis, and treatment of heart attack.

For more information, visit www.nihseniorhealth.gov. ■

Even though the company had not completed its root-cause analysis, it decided to notify physicians, patients, and the FDA of the potential problem. An analysis of the retrieved devices should be completed by the fall, according to the FDA.

The agency said in a statement that it backed Boston Scientific's plan to remove the devices from hospital inventories and to direct physicians to conduct follow-up exams with patients.

"While information about the problem

with these devices is still very preliminary, FDA is committed to keeping the public informed," said Dr. Daniel Schultz, director of the agency's Center for Radiological Devices and Health.

Dr. Dwight Reynolds, president of the Heart Rhythm Society, agreed that the company's move was prudent and in line with the task force's recommendations. "I think the fact that they've announced fairly early in their evaluation process that this problem exists is a testament to their


commitment to what everyone has espoused: that early disclosure of events is appropriate," Dr. Reynolds told INTERNAL MEDICINE NEWS.

The day after the society's draft was released, Boston Scientific, which had just completed its purchase of Guidant Corp., said that it would follow all of the recommendations.

Guidant's devices have been the subject of multiple safety notices and recalls since early 2005, including the one in June. The

One profile was created

The other was earned



company has been repeatedly criticized for a failure to notify physicians or patients on a timely basis.

The perception that the devices are unsafe has led to anxiety among patients, Dr. Reynolds said. Although the numbers of those who have sought explantation or refused implantation are hard to quantify, he said he has heard many anecdotal reports. A colleague told him last fall that two patients who were ICD candidates told the cardiologist they would not consider the implants "because they don't trust them." The fear seems to have dissipated recently, however, he said.

He added that physicians have been

concerned about quality issues and have reflected that concern in less enthusiasm for implanting the Guidant devices. But, he said, it's not an attitude that is "either pervasive or likely to be sustained."

And both he and Dr. Carlson said that Boston Scientific is doing a good job of moving forward.

"I think they've now acknowledged that the patients' and physicians' right to know supersedes concerns about what their responses might be," Dr. Reynolds said.

Physicians have been concerned about the communications process in the last year, Dr. Carlson said. However, he added, "I'm hopeful and extremely optimistic

that those problems are behind us."

Dr. Carlson has consulting or speaking relationships with Guidant, St. Jude Medical Inc., and Medtronic Inc. Dr. Reynolds is a consultant, and has received honoraria as a speaker, for Medtronic.

Boston Scientific also recently has hired someone to be a point person on product safety: William E. Young, who will have the title of vice president of quality assurance and reliability for the cardiac rhythm management group.

The Heart Rhythm Society's guidelines are expected to be published in October, most likely in the society's journal, *Heart Rhythm*, Dr. Carlson said. ■

VERBATIM

'While the American people worry about the safety of drugs, the top FDA leadership tells us we need fast drug approval.'

Dr. Steven Nissen, on concerns that commercial influences are undermining public confidence in the FDA, p. 60


Lantus®: the #1-prescribed insulin for good reason

The #1 priority for people with diabetes-related hyperglycemia is to reduce blood glucose and A1C.¹

Over the past 5 years, physicians like you have turned to Lantus® in steadily increasing numbers to do just that.* Why? Because 5 years ago when you were wishing for a basal insulin that mimicked the way physiologic basal insulin works, Lantus® came along. It was then, and is still, the only once-daily, 24-hour basal insulin with no pronounced peak.² The result? Millions of prescriptions have been written for Lantus®.* Lantus®, along with diet, exercise, and prandial and/or oral agents, allows patients to benefit from a full 24 hours of glucose lowering. Studies have shown Lantus® is associated with a low rate of hypoglycemia and has a neutral effect on weight.²⁻⁴

Lantus® closely mimics physiologic basal insulin secretion.^{3,6}

Physiologic basal insulin is secreted continuously over 24 hours, at a rate of approximately 0.5 IU/h, to meet between-meal and overnight glucose-regulating requirements and to suppress excess hepatic glucose production.⁶ Past attempts at creating an insulin to mimic this profile have resulted in agents that have wide variability in their absorption and length of effect. Lantus® demonstrates a low rate of variability in its action, with a relatively flat, predictable profile after only 1 injection that lasts for a full 24 hours.^{2,7,8} Additionally, in a crossover study of healthy volunteers, no differences in absorption rates were observed whether Lantus® was injected into the leg, arm, or abdomen.^{2,9}



Physiologic basal profile means patients are better able to plan when to eat—because they don't have to contend with insulin peaks.⁶ That can help patients by not requiring them to eat or snack at a specific time to balance a peak. In fact, Lantus® is associated with a low rate of hypoglycemia. It also has a neutral effect on weight.

Lantus®, a basal insulin for patients with diabetes, has the features you want. It's what you've told us.

It's what you've *shown* us by making Lantus® the #1-prescribed insulin.

Lantus® is the only once-daily, 24-hour basal insulin with no pronounced peak, and it closely mimics physiologic basal insulin secretion.²

It's tried. It's trusted. And it's there for you as you help

more and more patients with diabetes toward control of blood glucose.

We thank you for letting Lantus® help.

Once-Daily
24-HOUR
LANTUS®
insulin glargine [rDNA origin] injection

Important Safety Information

Lantus® is indicated for once-daily subcutaneous administration, at the same time each day, for the treatment of adult and pediatric patients (6 years and older) with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia.

LANTUS® MUST NOT BE DILUTED OR MIXED WITH ANY OTHER INSULIN OR SOLUTION. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner.

Lantus® is contraindicated in patients hypersensitive to insulin glargine or the excipients.

Hypoglycemia is the most common adverse effect of insulin, including Lantus®. As with all insulins, the timing of hypoglycemia may differ among various insulin formulations. Glucose monitoring is recommended for all patients with diabetes. Any change of insulin type and/or regimen should be made cautiously and only under medical supervision. Concomitant oral antidiabetes treatment may need to be adjusted.

Other adverse events commonly associated with Lantus® include the following: lipodystrophy, skin reactions (such as injection-site reaction, pruritus, rash), and allergic reactions.

Please see brief summary of prescribing information on adjacent page.

*Based on PNRx. IMS Health. *National Prescription Audit Plus™*. September 2003 – December 2005.

References: 1. American Diabetes Association. *Diabetes Care*. 2005;28(suppl 1):S4-S36. 2. Lantus Prescribing Information. 3. Data on file, sanofi-aventis U.S. LLC (CSR HOE901/5001). 4. Data on file, sanofi-aventis U.S. LLC (CSR HOE901/5024). 5. Nathan DM. *N Engl J Med*. 2002;347:1342-1349. 6. Guthrie R. *Clin Diabetes*. 2001;19:66-70. 7. Scholtz HE, Pretorius SG, Wessels DH, Becker RHA. *Diabetologia*. 2005;48:1988-1995. 8. Fanelli CG, Pampanelli F, Porcellati P, et al. Poster presented at: 38th Annual Meeting of the European Association for the Study of Diabetes (EASD); September 1-5, 2002; Budapest, Hungary. 9. McKeage K, Goa KL. *Drugs*. 2001;61:1599-1624.